Solid Target Technologies For Medical Cyclotrons

Solid Target Manufacturing


Solid targetry for Tc-99m, Ga-68 and Cu-64 isotope production.

Solid Target Transportation


Reliable and compact pneumatic transfer system for solid targets.

Isotope Separation Systems


Dissolution and purification processes to extract isotopes for diagnostic imaging.

ABOUT US

ARTMS™ Products is a leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotopes. Our flagship product is the QUANTM99, a hardware and consumable system for producing Tc-99m on medical cyclotrons to enable cost-effective, decentralized, and local production of medical isotopes.

MEDICAL ISOTOPE PRODUCTION
NUCLEAR CHEMISTRY
QUALITY ANALYTICS
REGULATORY COMPLIANCE
INDUSTRY ENGAGEMENT

LEADERSHIP

Frank Gleeson, MBA

Director Mr. Frank Gleeson has more than 20 years of leadership and…

Paul Schaffer, PHD

Founding CEO Dr. Paul Schaffer is CEO of ARTMS Products and Head…

Steven Foster, MBA

Chair of the Board Mr. Steven Foster is the Business Manager at…

ARTMS TECHNOLOGY

In 2007 & 2009 the world experienced shortages due to reactor outages, highlighting the vulnerability of the current supply chain. The shortages caused in significant price increases, delayed and canceled medical procedures and resulted in a decrease in patient care. In response, ARTMS Products Inc. developed an award-winning, first-to-market, locally deployable method for producing Tc-99m using existing, hospital-based medical cyclotrons. ARTMS holds the exclusive global commercialization rights to the award-winning and proprietary Canadian technology that addresses these challenges and offers the prospect of revolutionizing the nuclear medicine industry.

FEATURED ARTICLES

Researchers at the BC Cancer Agency in Vancouver and TRIUMF, the Canadian national particle and nuclear physics lab, have successfully produced vital supplies of Technetium-99m, a medical imaging isotope, using a retrofitted cyclotron, a type of particle accelerator already in […]

A Canadian-led team says that it has succeeded in proving the feasibility of using particle accelerators instead of nuclear reactors to produce a badly needed medical isotope. If health regulators approve the method, it will place supplies of the crucial […]

The first commercial shipment of medical isotopes produced using a new particle-accelerator-based technique has been made by scientists at the Canadian Light Source (CLS). Molybdenum-99 (Mo-99) decays to create technetium-99m (Tc-99m), which is used to tag radiopharmaceuticals and plays a […]

See all our news

AWARDS

For outstanding teamwork in realizing a solution for safe and reliable isotope production for hospitals in Canada, Dr. Paul Schaffer, along with five other distinguished colleagues, received the prestigious NSERC Brockhouse Canada Prize on behalf of a collaborative effort between their respective institutions. The Prize was awarded for Interdisciplinary Research in Science and Engineering by His Excellency the Right Honourable David Johnston, the 28th Governor General of Canada.

TWITTER

PARTNERS

inline-flex